All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), immune chekpoint inhibitors vs. placebo plus SoC, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.83 [0.69; 1.00]
0.83 [0.69 ; 1.00 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable progression or deaths (PFS)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.82 [0.70; 0.96]
0.82 [0.70 ; 0.96 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable CRR detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [1.21; 3.17]
1.96 [1.21 ; 3.17 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable DORdetailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.70 [0.46; 1.08]
0.70 [0.46 ; 1.08 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 386 NA not evaluable objective responses (ORR)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.15 [0.88; 1.51]
1.15 [0.88 ; 1.51 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 851 NA not evaluable AE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.34 [0.43; 12.83]
2.34 [0.43 ; 12.83 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.92 [0.63; 1.34]
0.92 [0.63 ; 1.34 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable AE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.27 [0.70; 2.27]
1.27 [0.70 ; 2.27 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.05 [0.79; 1.40]
1.05 [0.79 ; 1.40 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 850 NA not evaluable SAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.85; 1.46]
1.11 [0.85 ; 1.46 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable STRAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.33 [0.99; 1.80]
1.33 [0.99 ; 1.80 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable TRAE (any grade)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.04 [0.53; 2.03]
1.04 [0.53 ; 2.03 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.02 [0.72; 1.43]
1.02 [0.72 ; 1.43 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable TRAE leading to death (grade 5)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.96 [0.60; 6.40]
1.96 [0.60 ; 6.40 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.67; 1.84]
1.11 [0.67 ; 1.84 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.00 [0.82; 4.92]
2.00 [0.82 ; 4.92 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.59 [0.27; 25.03]
2.59 [0.27 ; 25.03 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.61 [0.70; 9.73]
2.61 [0.70 ; 9.73 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.73 [0.31; 9.49]
1.73 [0.31 ; 9.49 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.01 [1.12; 3.62]
2.01 [1.12 ; 3.62 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Pruritus TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.72 [0.06; 51.51]
1.72 [0.06 ; 51.51 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Rash TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.86 [0.02; 43.49]
0.86 [0.02 ; 43.49 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.11 [0.55; 2.26]
1.11 [0.55 ; 2.26 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Anaemia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.08 [0.82; 1.42]
1.08 [0.82 ; 1.42 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Asthenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.43 [0.81; 2.50]
1.43 [0.81 ; 2.50 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Fatigue AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.66 [0.37; 1.17]
0.66 [0.37 ; 1.17 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.76 [0.81; 3.80]
1.76 [0.81 ; 3.80 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Hypertension AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 2.22 [1.05; 4.68]
2.22 [1.05 ; 4.68 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.74 [0.44; 1.24]
0.74 [0.44 ; 1.24 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Nausea AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.54 [0.23; 1.27]
0.54 [0.23 ; 1.27 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.38 [1.03; 1.84]
1.38 [1.03 ; 1.84 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 1.25 [0.89; 1.76]
1.25 [0.89 ; 1.76 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable Vomiting AE (grade 3-4)detailed results IMvigor-130 (At-arm A vs Pl-arm C), 2020 0.86 [0.37; 2.00]
0.86 [0.37 ; 2.00 ] IMvigor-130 (At-arm A vs Pl-arm C), 2020 1 0% 843 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 22:54 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743